| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Lenacapavir Cyclosporine | Yellow: Adjust dosing | Minimal data to guide interaction: weigh risks and benefits of using this combination | Potential increased risk of immunosuppressant adverse effects |
Initiate adjusted dose of immunosuppressant to account for increased concentration and follow up with therapeutic drug monitoring to refine dosing. Monitor for adverse effects of immunosuppressant. Consult with specialist as necessary. |
|||
| Darunavir CsA 1011 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits of using this combination | Potential for increased risk of cyclosporine adverse effects (supratherapeutic immunosuppression, renal toxicity) |
Not studied |
Not studied (may increase cyclosporine levels) |
If coadministering, initiate lower dose of immunosuppressant, monitor concentrations and toxicity, consult with specialist, and adjust dose as necessary |
|
| Nevirapine CsA 642 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits when using this combination | decreased effects of immunosuppresant |
if co administiring, monitor immunosuppressant efficacy |
|||
| Efavirenz CsA 509 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits when using this combination | decreased effects of immunosuppresant |
if co administiring, monitor immunosuppressant efficacy |
|||
| Efavirenz CsA 508 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits when using this combination | decreased effects of immunosuppresant |
if co administiring, monitor immunosuppressant efficacy |
|||
| Efavirenz CsA 507 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits when using this combination | decreased effects of immunosuppresant |
if co administiring, monitor immunosuppressant efficacy |
|||
| Elvitegravir CsA 271 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits of using this combination | Potential for increased cyclosporine toxicity |
Not reported |
If coadministering, initiate lower dose of immunosuppressant, therapeutic drug monitoring is recommended, assess toxicity, consult with specialist, and adjust dose as necessary |
